On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through the long-touted move via an executive order.
There is a frustrating misimpression circulating in the cannabis community regarding rescheduling.
A group of leading US cannabis companies is suing the federal government in an attempt to overturn the country-wide prohibition of cannabis.
A new bi-partisan bill which would see cannabis removed from the Controlled Substances Act (CSA) federally, and enshrine each US state with the ability to determine the best approach for legalisation has been put forward by Rep.
